[go: up one dir, main page]

WO2009012039A2 - Polymorphes cristallins - Google Patents

Polymorphes cristallins Download PDF

Info

Publication number
WO2009012039A2
WO2009012039A2 PCT/US2008/068558 US2008068558W WO2009012039A2 WO 2009012039 A2 WO2009012039 A2 WO 2009012039A2 US 2008068558 W US2008068558 W US 2008068558W WO 2009012039 A2 WO2009012039 A2 WO 2009012039A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
another embodiment
embodiment provides
pharmaceutical composition
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/068558
Other languages
English (en)
Other versions
WO2009012039A3 (fr
Inventor
Joseph J. Kopcho
Scott J. Hecker
Patricia Frech
Mike Deason
Qun Dang
Karen Gushurst
Donglai Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of WO2009012039A2 publication Critical patent/WO2009012039A2/fr
Publication of WO2009012039A3 publication Critical patent/WO2009012039A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Definitions

  • the present invention relates to crystalline polymorphs of a phosphorus-containing 5-ketothiazole compound that is a potent inhibitor of fructose- 1,6-bisphosphatase (FBPase) and pharmaceutical compositions thereof as well as methods of making and using the same.
  • FBPase fructose- 1,6-bisphosphatase
  • a compound may exist in an amorphous state or in a crystalline state.
  • a crystalline form of an API may be polymorphic.
  • a polymorph is a compound of a defined chemical composition that exists in more than one molecular arrangement or configuration in the solid state.
  • the present invention provides for novel crystalline polymorphic forms, or polymorphs, (Forms A-E) of 2-amino-5-(2,2-dimethylpropionyl)-4- ⁇ [5-(N,N-(2-ethoxy- carbonylprop-2-yl)phosphonamido] furan-2-yl ⁇ thiazole (the compound of Formula I) and pharmaceutical compositions and medicaments of the same. Further provided are methods of using the polymorph Forms A-E of the compound of Formula I (herein after, simply Forms A-E) in the treatment of patients in need thereof. The invention further provides for processes of making Forms A-E. BRIEF DESCRIPTION OF THE DRAWINGS
  • Figure 3. X-ray diffraction pattern of Form B.
  • Figure 4. XRPD pattern of Form B (calculated pattern from single crystal data).
  • FIG. 5 Comparison of the experimental to the calculated XRPD pattern of Form B.
  • the top pattern is an experimental XPRD.
  • the bottom pattern is calculated form single crystal data.
  • Animal includes birds and mammals, in one embodiment a mammal, including a dog, cat, cow, horse, goat, sheep, pig or human. In one embodiment the animal is a human. In another embodiment the animal is a male. In another embodiment the animal is a female.
  • ''Diabetes refers to a heterogeneous group of disorders that share glucose intolerance in common. It refers to disorders in which carbohydrate utilization is reduced and that of lipid and protein enhanced; and may be characterized by hyperglycemia, glycosuria, ketoacidosis, neuropathy or nephropathy, increased hepatic glucose production, insulin resistance in various tissues, insufficient insulin secretion and enhanced or poorly controlled glucagon secretion from the pancreas.
  • Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision.
  • the vast majority of cases of diabetes fall into two broad etiopatho genetic categories.
  • type 1 diabetes the cause is an absolute deficiency of insulin secretion.
  • Individuals at increased risk of developing this type of diabetes can often be identified by serological evidence of an autoimmune pathologic process occurring in the pancreatic islets and by genetic markers.
  • type 2 diabetes the cause is a combination of resistance to insulin action and an inadequate compensatory insulin secretory response.
  • a degree of hyperglycemia sufficient to cause pathologic and functional changes in various target tissues, but without clinical symptoms, may be present for a long period of time before diabetes is detected.
  • this asymptomatic period it is possible to demonstrate an abnormality in carbohydrate metabolism by measurement of plasma glucose in the fasting state or after a challenge with an oral glucose load.
  • Criteria for the diagnosis of diabetes include: 1. Symptoms of diabetes plus casual plasma glucose concentration 200 mg/dl (1 1.1 mmol/1).
  • FPG 126 mg/dl (7.0 mmol/1). Fasting is defined as no caloric intake for at least 8 h; or
  • Etiologic classification of diabetes mellitus are as follows: I. Type 1 diabetes ( ⁇ -cell destruction, usually leading to absolute insulin deficiency) A. Immune mediated B. Idiopathic II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin deficiency to a predominantly secretory defect with insulin resistance) ITI. Other specific types
  • GDM Gestational diabetes mellitus
  • Insulin resistance is defined clinically as the impaired ability of a known quantity of exogenous or endogenous insulin to increase whole body glucose uptake and utilization.
  • IGT Internet glucose tolerance
  • a condition known to precede the development of overt Type 2 diabetes It is characterized by abnormal blood glucose excursions following a meal.
  • the current criteria for the diagnosis of IGT are based on 2-h plasma glucose levels post a 75g oral glucose test (144-199 mg/dL). Although variable from population to population studied, IGT progresses to full-blown NIDDM at a rate of 1.5 to
  • IGT is an independent risk factor for the development of cardiovascular disease.
  • Metabolic Syndrome X or "The Metabolic Syndrome” is characterized by a group of metabolic risk factors in one person. They include:
  • Insulin resistance or glucose intolerance the body can't properly use insulin or blood sugar
  • Prothrombotic state e.g., high fibrinogen or plasminogen activator inhibitor [-1J in the blood
  • Proinflammatory state e.g., elevated high-sensitivity C -reactive protein in the blood
  • “Metabolic Syndrome” or “Metabolic Syndrome X” is identified by the presence of three or more of these components: • Central obesity as measured by waist circumference:
  • Fasting glucose greater than or equal to 110 mg/dL ''Preventing includes a slowing of the progress or development of a disease before onset or precluding onset of a disease.
  • Therapeutically effective amount means an amount of a compound or a combination of compounds that ameliorates, attenuates or eliminates one or more of the symptoms of a particular disease or condition or prevents, modifies, or delays the onset of one or more of the symptoms of a particular disease or condition.
  • Treatment includes a slowing of the progress or development of a disease after onset or actually reversing some or all of the disease affects. Treatment also includes palliative treatment.
  • Type 1 diabetes (formerly known as “childhood,” “juvenile,” “insulin-dependent” diabetes) is a form of diabetes characterized by an absolute deficiency of insulin secretion. Individuals at increased risk of developing this type of diabetes can often be identified by serological evidence of an autoimmune pathologic process occurring in the pancreatic islets and by genetic markers. Type 1 diabetes may be caused by immune mediated beta-cell destruction, usually leading to absolute insulin deficiency or may be idiopathic, having no known etiologies.
  • Type 2 diabetes refers to a heterogeneous disorder characterized by impaired insulin secretion by the pancreas and insulin resistance in tissues such as the liver, muscle and adipose tissue.
  • the manifestations of the disease include one or more of the following: impaired glucose tolerance, fasting hyperglycemia, glycosuria, decreased levels of insulin, increased levels of glucagon, increased hepatic glucose output, reduced hepatic glucose uptake and glycogen storage, reduced whole body glucose uptake and utilization, dyslipidemia, fatty liver, ketoacidosis, microvascular diseases such as retinopathy, nephropathy and neuropathy, and macrovascular diseases such as coronary heart disease.
  • the present invention relates to polymorph Forms A-E.
  • the invention provides for a composition consisting of, consisting essentially of or comprising Forms A.
  • the invention provides for a composition consisting of, consisting essentially of or comprising Form B. In one embodiment, the invention provides for a composition consisting of, consisting essentially of or comprising Form C.
  • the invention provides for a composition consisting of, consisting essentially of or comprising Form D.
  • the invention provides for a composition consisting of. consisting essentially of or comprising Form E.
  • Another embodiment provides for a composition comprising Forms A and B.
  • Another embodiment provides for a composition comprising Forms A and C.
  • Another embodiment provides for a composition comprising Forms A and D.
  • Another embodiment provides for a composition comprising Forms A and E. Another embodiment provides for a composition comprising Forms B and C.
  • Another embodiment provides for a composition comprising Forms B and D.
  • Another embodiment provides for a composition comprising Forms B and E.
  • Another embodiment provides for a composition comprising Forms C and D.
  • Another embodiment provides for a composition comprising Forms C and E. Another embodiment provides for a composition comprising Forms D and E.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 50% of said Formula 1 is Form A.
  • Another embodiment provides for a composition comprising Formula 1. wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
  • Another embodiment provides for a composition comprising Formula 1, wherein at least 80% of said Formula 1 is Form A.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides for a composition comprising Formula 1, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 70%) of said Formula I is Form B. Another embodiment provides for a composition comprising Formula 1, wherein at least 75%o of said Formula I is Form B.
  • compositions comprising Formula I, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides for a composition comprising Formula 1, wherein at least 90% of said Formula 1 is Form B.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 95%o of said Formula 1 is Form B.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 98% of said Formula I is Form B. Another embodiment provides for a composition comprising Formula I, wherein at least 50%) of said Formula I is Form C.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 70%o of said Formula I is Form C. Another embodiment provides for a composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 80% of said Formula I is Form C. Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
  • Another embodiment provides for a composition comprising Formula 1, wherein at least 95% of said Formula I is Form C.
  • Another embodiment provides for a composition comprising Formula 1, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides for a composition comprising Formula 1. wherein at least 70% of said Formula I is Form D. Another embodiment provides for a composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
  • compositions comprising Formula I, wherein at least 80% of said Formula 1 is Form D.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides for a composition comprising Formula 1, wherein at least 95% of said Formula 1 is Form D.
  • Another embodiment provides for a composition comprising Formula I 5 wherein at least 98%) of said Formula I is Form D.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 50% of said Formula 1 is Form E.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides for a composition comprising Formula 1, wherein at least 75% of said Formula I is Form E.
  • compositions comprising Formula I, wherein at least 80% of said Formula 1 is Form E.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form E. Another embodiment provides for a composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides for a composition comprising Formula I, wherein at least 98% of said Formula I is Form E. Another embodiment provides for a composition comprising Formula I, wherein said
  • Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula 1 is Form ⁇ .
  • compositions comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form A.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form A.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form A.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form A.
  • compositions comprising Formula 1, wherein said
  • Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form A.
  • compositions comprising Formula I. wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula 1 is Form A.
  • compositions comprising Formula I. wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form A.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form A.
  • compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form A.
  • compositions comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form B.
  • compositions comprising Formula T, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form B.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form B.
  • compositions comprising Formula I, wherein said
  • Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form B.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form B.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form B.
  • compositions comprising Formula 1, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form B.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form B.
  • compositions comprising Formula I, wherein said
  • Formula I comprises at least one crystalline form selected from Forms A-E. and wherein less than 2% of said Formula I is Form B.
  • compositions comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1 % of said Formula I is Form B.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form C.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula 1 is Form C.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form C.
  • compositions comprising Formula T, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula i is Form C.
  • compositions comprising Formula I. wherein said
  • Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form C.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form C.
  • compositions comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form C.
  • compositions comprising Formula 1, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form C.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form C.
  • compositions comprising Formula I, wherein said
  • Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula 1 is Form C.
  • compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form D.
  • compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form D.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form D.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form D.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form D.
  • compositions comprising Formula I, wherein said
  • Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form D.
  • compositions comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form D.
  • compositions comprising Formula I. wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form D.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form D.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1 % of said Formula I is Form D.
  • compositions comprising Formula T, wherein said
  • Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form E.
  • compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form E.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form E.
  • compositions comprising Formula 1. wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form E.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form E.
  • compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form E.
  • compositions comprising Formula I. wherein said
  • Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form E.
  • compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form E.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form E.
  • compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form E.
  • composition of the present invention is a pharmaceutical composition comprising Form A and a pharmaceutically acceptable excipient.
  • composition of the present invention is a pharmaceutical composition comprising Form B and a pharmaceutically acceptable excipient.
  • composition of the present invention is a pharmaceutical composition comprising Form C and a pharmaceutically acceptable excipient.
  • a composition of the present invention is a pharmaceutical composition comprising Form D and a pharmaceutically acceptable excipient. In another embodiment, a composition of the present invention is a pharmaceutical composition comprising Form E and a pharmaceutically acceptable excipient.
  • Another embodiment provides for a pharmaceutical composition comprising Forms A and B and a pharmaceutically acceptable excipient. Another embodiment provides for a pharmaceutical composition comprising Forms A and C and a pharmaceutical) y acceptable cxcipient.
  • Another embodiment provides for a pharmaceutical composition comprising Forms A and D and a pharmaceutically acceptable excipicnt. Another embodiment provides for a pharmaceutical composition comprising Forms A and E and a pharmaceutically acceptable excipient.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Forms B and C and a pharmaceutically acceptable excipient.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Forms B and D and a pharmaceutically acceptable excipient.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Forms B and E and a pharmaceutically acceptable excipient.
  • Another embodiment provides for a pharmaceutical composition comprising Forms C and D and a pharmaceutically acceptable excipient. Another embodiment provides for a pharmaceutical composition comprising Forms C and E and a pharmaceutically acceptable excipient.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Forms D and E and a pharmaceutically acceptable excipient.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient. wherein at least 80% of said Formula 1 is Form A.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula 1 is Form A.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 75% of said Formula 1 is Form B.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 80% of said Formula 1 is Form B.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form B.
  • Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula 1 is Form C.
  • Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form C.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula 1 is Form C.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 75% of said Formula 1 is Form D.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula 1 is Form E.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 70% of said Formula 1 is Form H.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form E.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula I is Form E.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Formula I comprises at least one crystalline form selected from Forms A-E. and wherein less than 50% of said Formula I is Form A.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula 1 is Form A.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-H, and wherein less than 30% of said Formula I is Form ⁇ .
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form A.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form A.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form A.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form A.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form A.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form A.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form A.
  • Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula 1 is Form B.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form B.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form B.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form B.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form B.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form B.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form B.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form B.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form B.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form B.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula T comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient.
  • said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form C.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form C.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form C.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form C.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form C.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form C.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula 1 is Form C.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms ⁇ -E, and wherein less than 2% of said Formula 1 is Form C.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form C.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula 1 is Form D.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form D.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient.
  • said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula 1 is Form D.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form D.
  • a pharmaceutical composition comprising Formula I
  • Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form D.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form D.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula 1 is Form D.
  • compositions comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula 1 is Form D,
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form D.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form D.
  • a pharmaceutical composition comprising Formula I
  • Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form E.
  • compositions comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form E,
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form E.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form E.
  • Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form E.
  • Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form E.
  • Another embodiment provides for a pharmaceutical composition comprising Formula
  • Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form E.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula 1 is Form E.
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E. and wherein less than 2% of said Formula I is
  • Another embodiment provides for a pharmaceutical composition
  • a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form E.
  • Another embodiment provides for the use of any one or more of Forms A-E for the manufacture of a medicament for the prevention, treatment or reduction of the time to onset of a disease or clinical condition for which an FBPase inhibitor(s) is indicated.
  • Another embodiment provides for the use of any one or more of Forms A-E in the manufacture of a medicament for the treatment, prevention or reduction of the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels.
  • Another embodiment provides for a method of treating, preventing or reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
  • Another embodiment provides for a method of for treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides for a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels. the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogcncsis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said f ormula I is Form B.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is
  • Another embodiment provides a method oO ' treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula T, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form D.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form D.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is
  • Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said
  • Formula I is Form A.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1. wherein at least 70% of said
  • Formula I is Form A.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gl ⁇ coneogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form ⁇ .
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula i is Form A.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula T, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 70% of said
  • Formula I is Form B.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said
  • Formula I is Form B.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said
  • Formula 1 is Form B.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said
  • Formula I is Form B.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels. the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
  • Formula I is Form B.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said
  • Formula I is Form B.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said
  • Formula I is Form C.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said
  • Formula I is Form C.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said
  • Formula I is Form C.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said
  • Formula 1 is Form C.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 90% of said
  • Formula 1 is Form C.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
  • Formula I is Form C.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconcogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula 1 is Form C.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form C.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form D.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form D.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
  • Formula 1 is Form D.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said
  • Formula I is Form D.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said
  • Formula 1 is Form D.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said
  • Formula 1 is Form E.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said
  • Formula I is Form E.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said
  • Formula 1 is Form E.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form R.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels. the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said
  • Formula I is Form E.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
  • Formula 1 is Form E.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 98% of said
  • Formula I is Form E.
  • Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said
  • Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 75% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form A.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula L wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form C.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form C.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula i, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of treating, preventing or reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a Form C.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 98% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form B.
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form B.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form B.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form B.
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form C.
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form C.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C .
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form D,
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula 1 is Form E.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form E.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form E.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form E.
  • Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
  • Another embodiment pro ⁇ des a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form E.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form A.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form A.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
  • Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form A.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeuticall) effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
  • Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form B.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula 1 is Form B.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form C.
  • Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of preventing lype I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of preventing fype I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E,
  • Another embodiment provides a method of preventing ' lype I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula 1 is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type ⁇ diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula i is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type T diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula 1 is Form E.
  • Another embodiment provides a method of reducing the time to onset of T>pe 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula i is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form H.
  • Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form R.
  • Another embodiment provides a method of treating, preventing or reducing the time to onset of Type 11 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
  • Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B. Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B. Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B .
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form B.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides a method of treating Type 11 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form C.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutical! ⁇ ' effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form E.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form E.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, w r herein at least 98% of said Formula I is Form E.
  • Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type 11 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering Io an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a melhod of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B,
  • Another embodiment provides a method of preventing Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula T, wherein at least 95% of said Formula I is
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 98% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form C.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 50% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1. wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 90% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form E.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form ⁇ .
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form ⁇ .
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides a method of inducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form D.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Fo ⁇ n E.
  • Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
  • Another embodiment provides a method of treating, preventing or reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of preventing Metabolic Syndrome X 5 the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a Form C. Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D. Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Fo ⁇ n E.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form B.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Fo ⁇ nula I, wherein at least 80% of said Formula I is Fo ⁇ n D.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form D.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Fonnula 1 is Form D.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form E,
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Fo ⁇ n E.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
  • Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form B.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form D.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula 1 is Form D.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Fo ⁇ nula I is Form D.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pha ⁇ naceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pha ⁇ naceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
  • Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form A.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X
  • Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A.
  • Another embodiment provides a method of reducing the time to onset of Metabolic
  • Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Fo ⁇ nula I, wherein at least 50% of said Fo ⁇ nula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B.
  • Another embodiment provides a method of reducing the time to onset of Metabolic
  • Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form C.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Metabolic
  • Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of Metabolic
  • Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Fo ⁇ n D.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form D.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Metabolic
  • Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X
  • Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form E.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
  • Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form E.
  • Another embodiment provides a method of treating, preventing or reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pha ⁇ naceutical composition comprising Form D.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Fo ⁇ nula I is Form B.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form E.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
  • Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form B.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Fo ⁇ nula I is Form C.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form D.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Fo ⁇ nula I is Form D.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
  • Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form E.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pha ⁇ naceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form A.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pha ⁇ naceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form B.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form C.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula 1 is Form D.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula 1 is Form D.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form D.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form E.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Fo ⁇ nula I, wherein at least 70% of said Formula 1 is Form E.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form E.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
  • Another embodiment provides a method of treating, preventing or reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula 1 selected from Forms A-E.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form B.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form B.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is Form C.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form E.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
  • Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Fo ⁇ n A.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Fo ⁇ nula I is Form A.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Fo ⁇ nula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form B.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form B.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is Form B.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form C.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 99% of said Formula I is Form C.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form D.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form D.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form D.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form D.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
  • Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula 1 is Form A.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form B.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
  • Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formes cristallines de 2-amino-5-(2,2~ diméthylpropionyl)-4-{[5-(N,N'-(2-éthoxycarbonylprop-2-yl)phosphonamido] furan-2-yl}thiazole et des compositions en contenant y compris des compositions pharmaceutiques. La présente invention concerne également des procédés d'utilisation et des procédés de fabrication de telles formes cristallines.
PCT/US2008/068558 2007-07-13 2008-06-27 Polymorphes cristallins Ceased WO2009012039A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94968107P 2007-07-13 2007-07-13
US60/949,681 2007-07-13

Publications (2)

Publication Number Publication Date
WO2009012039A2 true WO2009012039A2 (fr) 2009-01-22
WO2009012039A3 WO2009012039A3 (fr) 2009-03-19

Family

ID=40260294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/068558 Ceased WO2009012039A2 (fr) 2007-07-13 2008-06-27 Polymorphes cristallins

Country Status (1)

Country Link
WO (1) WO2009012039A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011161030A1 (fr) 2010-06-21 2011-12-29 Sanofi Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40
WO2012004269A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament
WO2012004270A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament
WO2012010413A1 (fr) 2010-07-05 2012-01-26 Sanofi Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP3352762A4 (fr) * 2015-09-22 2019-06-05 Viking Therapeutics, Inc. Thérapies combinées à des inhibiteurs de production de glucose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
AU2005277479A1 (en) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011161030A1 (fr) 2010-06-21 2011-12-29 Sanofi Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40
WO2012004269A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament
WO2012004270A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament
WO2012010413A1 (fr) 2010-07-05 2012-01-26 Sanofi Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP3352762A4 (fr) * 2015-09-22 2019-06-05 Viking Therapeutics, Inc. Thérapies combinées à des inhibiteurs de production de glucose

Also Published As

Publication number Publication date
WO2009012039A3 (fr) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009012039A2 (fr) Polymorphes cristallins
JP5584705B2 (ja) Ｒ）−３−（４−（２−（２−メチルテトラゾール−５−イル）ピリジン−５−イル）−３−フルオロフェニル）−５−ヒドロキシメチルオキサゾリジン−２−オンリン酸二水素の結晶形
CN111432803B (zh) 包含血浆激肽释放酶抑制剂的剂型
KR101712758B1 (ko) 아폽토시스 신호-조절 키나제 억제제로서의 치환된 피리딘-2-카르복스아미드 화합물
EA026385B1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
CN109422752A (zh) 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
JP5400387B2 (ja) １−ベンゾイル−４−［２−［４−メトキシ−７−（３−メチル−１ｈ−１，２，４−トリアゾール−１−イル）−１−［（ホスホノオキシ）メチル］−１ｈ−ピロロ［２，３−ｃ］ピリジン−３−イル］−１，２−ジオキソエチル］−ピペラジンの結晶形
US11117875B2 (en) Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod
TWI703143B (zh) ４-（４-（１-異丙基-７-側氧基-１，４，６，７－四氫螺〔吲唑-５，４’-哌啶〕-１’-羰基）-６-甲氧基吡啶-２-基）苯甲酸之晶型
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
JP2016512518A (ja) ベムラフェニブ塩酸塩の固体形態
US6664267B1 (en) Crystalline fluoroquinolone arginine salt form
US10189870B2 (en) Crystalline form of oxazolidinone antibiotics and preparation method, composition and use thereof
US20210053951A1 (en) Salt Forms Of 4-Cyano-N-(4,4-Dimethylcyclohex-1-EN-1-YL)-6-(2,2,6,6-Tetramethyltetrahydro-2H-Pyran-4-YL)Pyridin-3-YL)-1H-Imidazole-2-Carboximide
WO2019134455A1 (fr) Nouvelle forme cristalline d'acalabrutinib, son procédé de préparation et son utilisation
US11149013B2 (en) Crystal form of urate transporter 1 inhibitor and preparation method and use thereof
TWI752980B (zh) 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型
US11234939B2 (en) Dosage forms comprising a plasma kallikrein inhibitor
WO2007149568A2 (fr) N-(4-chloro-3-méthyle-5-isoxazolyle)-2-[2-méthyle-4,5-(méthylènedioxy) phénylacétyle]-thiophène-3-sulfonamide crystallin
US8217172B2 (en) Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1H-benzo[d]imidazol-2-yl)urea
TW202003467A (zh) Urat-1抑制劑的新型鹽形式
CN110678464A (zh) 马赛替尼的晶型
US10526358B2 (en) Crystalline forms
KR20230048004A (ko) 옥사디아졸 화합물, 이의 제조방법, 약제학적 조성물 및 이의 용도
HK40064722A (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08781092

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08781092

Country of ref document: EP

Kind code of ref document: A2